Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
- 16 September 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (23), 7808-7816
- https://doi.org/10.1021/jm9007533
Abstract
Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharmacokinetics (PK) or lack of adequate tolerability at efficacious doses. We have developed a series of extremely potent and highly selective FLT3 inhibitors with good oral PK properties. The first series of compounds represented by 1 (AB530) was found to be a potent and selective FLT3 kinase inhibitor with good PK properties. The aqueous solubility and oral PK properties at higher doses in rodents were found to be less than optimal for clinical development. A novel series of compounds were designed lacking the carboxamide group of 1 with an added water solubilizing group. Compound 7 (AC220) was identified from this series to be the most potent and selective FLT3 inhibitor with good pharmaceutical properties, excellent PK profile, and superior efficacy and tolerability in tumor xenograft models. Compound 7 has demonstrated a desirable safety and PK profile in humans and is currently in phase II clinical trials.Keywords
This publication has 18 references indexed in Scilit:
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseBlood, 2009
- Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug DiscoveryJournal of Medicinal Chemistry, 2008
- FLT3 inhibitors for the treatment of autoimmune diseaseExpert Opinion on Investigational Drugs, 2008
- High-throughput kinase profiling as a platform for drug discoveryNature Reviews Drug Discovery, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- Features of Selective Kinase InhibitorsCell Chemical Biology, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002